Skip to main content

Advertisement

SpringerLink
Log in

Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences

  • Original Article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

The recently developed technetium-99m-labelled monoclonal antibody-170 (MAb-170) was designed for diagnostic use in patients suffering from gynaecological adenocarcinoma. Following in vitro studies which showed immunoreactivity of this antibody to more than 90% of human adenocarcinomas, the present investigation was initiated to verify its usefulness for radioimmunoscintigraphy of ovarian tumours. Most of the 30 patients participating in this study underwent immunoscintigraphy prior to first-look surgery. Biokinetic evaluation in two patients showed a plasma half-time of 18.9 h (mean value,n = 2,r = 0.98) and a biexponential total body curve with values of 7.7 h and 17 days (r = 0.98). The mean 24-h urinary excretion was 12% of the injected dose. Radioimmunoscintigraphy using the MAb-170 recognised 12 of 13 cases of adenocarcinoma of the ovaries, corresponding to an overall sensitivity of 92.3% . Specificity was 94.1% (16/17). The calculation of accuracy yielded a figure of 93.3% (28/30). Of 33 known lesions, 26 were visualised successfully; thus the locoregional sensitivity was 78.8%. Of 29 benign tumour sites, 28 showed no evidence of tracer accumulation, corresponding to a locoregional specificity of 96.6%. The smallest lesion visualised was an adenocarcinoma of the corpus uteri with a diameter of 1.5 cm. Technetium-99m labelled MAb-170 is a promising new radiopharmaceutical for immunoscintigraphy of ovarian adenocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Davies JO, Davies ER, Howe K, et al. Radionuclide imaging of ovarian tumours with123I-labelled monoclonal antibody (NDOG2) directed against placental alkaline phosphatase.Br J Obstet Gynaecol 1985; 92: 277–286.

    PubMed  Google Scholar 

  2. Pateisky N, Philipp K, Skodler WD, Czerwenka K, Hamilton G, Burchell J. Radioimmunodetection in patients with suspected ovarian cancer.J Nucl Med 1985; 26: 1369–1376.

    PubMed  Google Scholar 

  3. Epenetos AA, Shepherd J, Britton KE, et al.123I radioiodinated antibody imaging of occult ovarian cancer.Cancer 1985; 55:984–987.

    PubMed  Google Scholar 

  4. Chatal JF, Fumoleau P, Saccavini JC, et al. Immunoscintigraphy of recurrences of gynecologic carcinomas.J Nucl Med 1987;28: 1807–1819.

    PubMed  Google Scholar 

  5. Baum RP, Lorenz M, Hottenrott C, et al. Radioimmunoscintigraphy using monoclonal antibodies to CEA, CA 19-9 and CA125.Int J Biol Markers 1988; 3: 177–184.

    PubMed  Google Scholar 

  6. Lastoria S, D'Amico P, Mansi L, et al. A prospective imaging study of131I-B72.3 monoclonal antibody in patients with epithelial ovarian cancer: preliminary report.Nucl Med Conunun 1988;9:347–356.

    Google Scholar 

  7. Granowska M, Mather SJ, Jobling T, et al. Radiolabelled stripped mucin, SM3, monoclonal antibody for immunoscintigraphy of ovarian tumours.Int J Biol Markers 1990; 5: 89–96.

    PubMed  Google Scholar 

  8. Buist MR, Roos JC, Vermorken JB, Golding RP, Burger CW, Kenemans P. The diagnostic value of immunoscintigraphy using the monoclonal antibody OV-TL3 in patients with ovarian carcinoma.Ned Tijdschr Geneeskd 1991; 135: 126–130.

    PubMed  Google Scholar 

  9. Crippa F, Buraggi GL, Di-Re E, et al. Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody.Eur J Cancer 1991; 27: 724–729.

    PubMed  Google Scholar 

  10. Del-Vecchio S, Camera L, Petrillo A, et al. Clinical studies with B72.3 in ovarian cancer and probe-guided tumor localization.Int J Rad Appl Instrum [B] 1991; 18: 85–87.

    Google Scholar 

  11. Han B, Liu CG, Fang YX, et al. Radioimmunolocalization of human malignant tumors with In-111 labeled monoclonal antibody.Chin Med J (Engl) 1991; 104: 999–1004.

    Google Scholar 

  12. Trampert L, Villena C, Benz P, Keweloh HC, Schmidt W, Oberhausen E. A clinical evaluation of MAb BW 835/6 in breast and ovarian cancer.Nucl Med 1992; 31: 249–253.

    Google Scholar 

  13. Granowska M, Britton KE, Mather SJ, et al. Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer.Eur J Nucl Med 1993; 20:483–4889.

    PubMed  Google Scholar 

  14. MacLean GD, McEwan AL, Noujaim AA, et al. Two novel monoclonal antibodies have potential for gynecologic cancer imaging.Antibody Immunoconjugates Radiopharmaceuticals 1991;4:297–308.

    Google Scholar 

  15. McEwan AJB, MacLean GD, Hooper HR, et al. MAb 170H.82: an evaluation of a novel panadenocarcinoma monoclonal antibody labelled with99Tcm and with111In.Nucl Med Commun 1992; 13: 11–19.

    PubMed  Google Scholar 

  16. Barzen G, Mayr AC, Langer M, et al. Radioimmunoscintigraphy of ovarian cancer with 131-iodine labeled OC-125 antibody fragments.Eur J Nucl Med 1989; 15: 42–48.

    PubMed  Google Scholar 

  17. Barzen G, Cordes M, Langer M, Friedman W, Mayr AC, Felix R. Value of radioimmunoscintigraphy compared to computed tomography in the diagnosis and follow-up of primary ovarian carcinoma. Rofo Fortschr Geb Rontgenstr Nuklearmed 1990; 153: 85–91.

    PubMed  Google Scholar 

  18. Mansi L, Panza N, Lastoria S, Pacilio G, Salvatore M. Diagnosis of ovarian cancer with radiolabelled monoclonal antibodies: our experience using131-B72.3.Int J Rad Appl Instrum [B] 1989; 16: 127–135.

    Google Scholar 

  19. Pateisky N, Gitsch E. Immunoscintigraphy and intraoperative tumor search in ovarian cancer.Arch Gynecol Obstet 1989; 245:606–609.

    PubMed  Google Scholar 

  20. Jimenez-Vicioso A, Torres M, Jimenez-Heffernan A, et al. Immunoscintigraphy with131I or111In labelled OC 125 F(ab′)2 fragments in patients with ovarian carcinoma.Int J Biol Markers 1990; 5: 159–165.

    PubMed  Google Scholar 

  21. Lehtovirta P, Kairemo KJ, Liewendahl K, Seppala M. Immunolymphoscintigraphy and immunoscintigraphy of ovarian and fallopian tube cancer using F(ab′)2 fragments of monoclonal antibody OC 125. Cancer Res 1990; 50: 937s-940s.

    PubMed  Google Scholar 

  22. Massuger LF, Kenemans P, Claessens RA, et al. Immunoscintigraphy of ovarian cancer with indium-111- labeled OV-TL 3 F(ab′)2 monoclonal antibody.J Nucl Med 1990; 31: 1802–1810.

    PubMed  Google Scholar 

  23. Papazefkos V, Michalas S, Papantoniou V, et al. Comparative study of RIS with the131I-OC 125 F(ab′)2 Mab and CT scan prior to second look operation for ovarian cancer.Eur J Obstet Gynecol Reprod Biol 1990; 37: 271–277.

    PubMed  Google Scholar 

  24. Krag DN, Haseman MK, Ford P, et al. Gamma probe location of111indium-labeled B72.3: an extension of immunoscintigraphy.J Surg Oncol 1992; 51: 226–230.

    PubMed  Google Scholar 

  25. Tibben JG, Massuger LF, Claessens RA, et al. Tumour detection and localization using 99Tcm-labelled OV-TL 3 Fab′ in patients suspected of ovarian cancer.Nucl Med Commun 1992; 13: 885–893.

    PubMed  Google Scholar 

  26. Granowska M, Britton KE, Shepard JH, et al. A prospective study of I-123 labeled monoclonal antibody imaging in ovarian cancer.J Clin Oncol 1986; 4: 730–736.

    PubMed  Google Scholar 

  27. Kenemans P, Yedema CA, Hilgers JH, et al. Clinical applications of monoclonal antibodies against ovarian cancer-associated antigens.Eur J Obstet Gynecol Reprod Biol 1988; 29: 207–218.

    PubMed  Google Scholar 

  28. Zalutsky MR, Knapp RC, Bast RC Jr. Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody.Int J Rad Appl Instrum [B] 1988; 15: 431–437.

    Google Scholar 

  29. Kennedy SH, Soper ND, Mojiminiyi OA, Shepstone BJ, Barlow DH. Immunoscintigraphy of ovarian endometriosis. A preliminary study.Br J Obstet Gynoecol 1988, 95: 693–697.

    Google Scholar 

  30. Kennedy SH, Mojiminiyi OA, Soper ND, Shepstone BJ, Barlow DH. Immunoscintigraphy of endometriosis.Front Radiat Ther Oncol 1990; 24: 228–239.

    PubMed  Google Scholar 

  31. Veggian R, Fasolato S, Ménard S, et al. Immunohistochemical reactivity of a monoclonal antibody prepared against human ovarian carcinoma on normal and pathological female genital tissues.Tumori 1989; 75: 510–513.

    PubMed  Google Scholar 

  32. Bouvier JF, Pernod J, Rivoire M, Maiassi N. Serum levels of tumor markers and presence of human antimouse antibodies: implications for diagnosis and treatment with radiolabeled monoclonal antibodies.Cancer Detect Prev 1988; 13: 251–262.

    PubMed  Google Scholar 

  33. Brokelmann J, Bockisch A, Vogel J, et al. Immunoscintigraphy using CA 125 antibodies in the management of ovarian cancer.Arch Gynecol Obstet 1989; 244: 193–206.

    PubMed  Google Scholar 

  34. Gitsch E, Pateisky N, Schatten C. Diagnostic and intraoperative immunoscintigraphy in ovarian cancer.Eur J Obstet Gynecol Reprod Biol 1989; 32: 33–37.

    PubMed  Google Scholar 

  35. Muto MG, Lepisto EM, Van-den Abbeele AD, Knapp RC, Kassis AI. Influence of human antimurine antibody on CA 125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125.Am J Obstet Gynecol 1989; 161: 1206–1212.

    PubMed  Google Scholar 

  36. Gitsch E, Pateisky N. Radioimmunoscintigraphy in ovarian cancer: theoretical principles and clinical experiences.Arch Gynecol Obstet 1987; 242: 365–370.

    PubMed  Google Scholar 

  37. Hnatowich DJ, Chinol M, Siebecker DA, et al. Patient biodistribution of intraperitoneally administered yttrium-90-labeled antibody.J Nucl Med 1988; 29: 1428–1435.

    PubMed  Google Scholar 

  38. Haisma HJ, Moseley KR, Battaile AI, Griffiths TC, Zurawski VR, Knapp RC. Biodistribution, pharmacokinetics and imaging of131I-labelled OC125 in ovarian cancer.Int J Cancer Suppl 1988; 2: 109–113.

    PubMed  Google Scholar 

  39. Malamitsi J, Skarlos D, Fotiou S, et al. Intracavitary use of two radiolabeled tumor- associated monoclonal antibodies.J Nucl Med 1988; 29: 1910–1915.

    PubMed  Google Scholar 

  40. Bell J, Mojzisik C, Hinkle G Jr, Derman H, Schlom J, Martin E. Intraoperative radioimmunodetection of ovarian cancer using monoclonal antibody B72.3 and a portable gamma-detecting probe.Obstet Gynecol 1990; 76: 607–611.

    PubMed  Google Scholar 

  41. Greiner JW, Smalley RV, Borden EC, et al. Applications of monoclonal antibodies and recombinant cytokines for the treatment of human colorectal and other carcinomas.J Surg Oncol Suppl 1991; 2: 9–13.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Saarland University Medical School, Homburg, Germany

    Christof Alexander, Ludwin Trampert, Erich Oberhausen & Carl-Martin Kirsch

  2. Department of Obstetrics and Gynaecology, Saarland University Medical School, Germany

    Carlos E. Villena-Heinsen, Sabine Lung-Kurt & Werner Schmidt

Authors
  1. Christof Alexander
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlos E. Villena-Heinsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ludwin Trampert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sabine Lung-Kurt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Erich Oberhausen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carl-Martin Kirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Werner Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alexander, C., Villena-Heinsen, C.E., Trampert, L. et al. Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences. Eur J Nucl Med 22, 645–651 (1995). https://doi.org/10.1007/BF01254566

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01254566

Key words

Search

Navigation